How does testosterone therapy affect hematocrit and platelet count?

Testosterone Significantly Increases Hematocrit but Decreases Platelet Count

Testosterone therapy consistently elevates hematocrit through direct stimulation of erythropoiesis, with the magnitude of increase depending on formulation and dose, while paradoxically decreasing platelet counts despite increasing platelet reactivity. 1, 2

Effect on Hematocrit

Testosterone acts as a direct stimulus for red blood cell production. Hemoglobin levels increase by 15-20% during testosterone therapy, with hematocrit rising from subnormal to mid-normal ranges, primarily during the first 3 months of treatment. 1

Formulation-Dependent Risk

The route of administration critically determines erythrocytosis risk:

• Intramuscular injections: 43.8% of patients develop elevated hematocrit (>52%) 1
• Transdermal patches (nonscrotal): 15.4% develop elevated hematocrit 1
• Scrotal patches: 5.5% develop erythrocytosis 1
• Testosterone gel: Dose-dependent effect
  • 5 mg/day: 2.8% incidence
  • 10 mg/day: 17.9% incidence 1

Injectable testosterone undecanoate increases hematocrit up to 5%, while intermediate-acting esters (enanthate, cypionate) increase it up to 6.9%. 3

Clinical Significance and Monitoring

Elevated hematocrit above normal range poses serious cardiovascular risk through increased blood viscosity, potentially aggravating coronary, cerebrovascular, or peripheral vascular disease, particularly in elderly patients. 1 The risk amplifies in patients with pre-existing conditions like COPD that independently raise hematocrit. 1

Mandatory monitoring protocol per Endocrine Society guidelines: 2

• Baseline hematocrit measurement
• Recheck at 3-6 months after initiation
• Annual monitoring thereafter
• If hematocrit exceeds 54%, immediately stop therapy until it decreases to safe levels
• Evaluate for hypoxia and sleep apnea before reinitiating at reduced dose

Management options when erythrocytosis develops include dose reduction, temporary withholding of testosterone, therapeutic phlebotomy, or blood donation. 1 Reassuringly, no testosterone-associated thromboembolic events had been reported in the guideline literature through 2004, 1 though more recent data from the TRAVERSE trial (2025) suggests associations between testosterone-induced changes in blood cell counts and VTE risk. 4

Effect on Platelet Count

Testosterone decreases platelet counts, contrary to what might be expected given its prothrombotic reputation. 5, 6 In the TRAVERSE trial, testosterone therapy was associated with a significantly greater decrease in platelets compared to placebo. 4

Paradoxical Platelet Effects

Despite lowering platelet counts, testosterone has complex effects on platelet function:

• Increases platelet thromboxane A2 receptor density by 2-fold (from 0.95 to 2.10 pmol/mg protein), enhancing platelet aggregation responses 7
• Platelet size and total circulating platelet mass decrease with castration and normalize with testosterone replacement 8
• In animal models, castration significantly decreases platelet count (956 vs 834 × 10³/μL), platelet size, and megakaryocyte ploidy, all of which testosterone restores 8

Thrombotic Risk Despite Lower Counts

The apparent contradiction—lower platelet counts but increased thrombotic potential—is explained by enhanced platelet reactivity. Testosterone increases maximum platelet aggregation responses to thromboxane mimetics, with receptor density positively correlating with endogenous testosterone levels (r = 0.56, p < 0.001). 7

Initial testosterone treatment causes mild activation of the hemostatic system, with transient increases in prothrombin fragment F1.2 and antithrombin III, though these return to baseline after several months as a new equilibrium establishes. 5 Factor VII decreases by approximately 15% but remains within normal ranges. 6

Clinical Implications

Key Monitoring Points

Beyond hematocrit surveillance mandated by guidelines 2, 9, clinicians should recognize:

• Neutrophil and monocyte counts increase with testosterone therapy and correlate with VTE risk (OR 1.32 and 1.39 per SD increase, respectively) 4
• White blood cell counts remain unchanged overall 8
• The thrombotic risk stems from enhanced platelet reactivity and increased blood viscosity from elevated hematocrit, not from elevated platelet counts

Common Pitfalls

1. Assuming all formulations carry equal erythrocytosis risk: Injectable testosterone carries 3-8 times higher risk than transdermal preparations 1, 3
2. Overlooking baseline risk factors: Patients with COPD, sleep apnea, smoking history, higher BMI, or older age at initiation face substantially higher erythrocytosis risk 1, 3
3. Failing to recognize the monitoring timeline: Most hematocrit changes occur within the first 3 months, requiring early surveillance 1

The FDA label explicitly requires periodic hemoglobin and hematocrit monitoring in patients receiving long-term androgen administration to detect polycythemia. 9